期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿帕替尼引起支气管-食管瘘一例 被引量：4

Apatinib damages trachea-esophageal fistula in 1 case
下载PDF
导出
摘要 患者,男,喉癌术后1年余,喉癌复发,放疗后4个月,PET-CT提示喉癌复发,化疗1个疗程后,二次复发,化疗2个疗程后,二次进展,行相关靶向治疗,服用甲磺酸阿帕替尼片1个月后,出现支气管-食管瘘。 A male patient was suffered by laryngeal carcinoma recurrence diagnosed by PET-CT after 4 months of radiotherapy. After 1 course of chemotherapy, the lm＇yngeal carcinoma recurred ; after 2 course of chemotherapy, the symptom progressed. The patient was given related target therapy. After takingapatinib for a month, the patients suf- fered trachea-esophageal fistula.
作者 梁晓宇 苗秋丽 张越 张四喜 LIANG Xiao-yu;MIAO Qiu-li;ZHANG Yue;ZHANG Si-xi(Department of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China)
机构地区 吉林大学第一医院药学部
出处 《实用药物与临床》 CAS 2018年第9期1085-1086,共2页 Practical Pharmacy and Clinical Remedies
关键词 阿帕替尼 支气管-食管瘘 喉癌 不良反应 Apatinib Trachea-esophageal fistula Laryngeal carcinoma Adverse reaction
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献3

二级参考文献62

  • 1黄静,任榕娜.细胞色素P450酶系与抗癫痫药物的代谢[J].国际儿科学杂志,2006,33(3):167-169. 被引量：8
  • 2LEVITZKI A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance [J]. Annu Rev Pharmacol Toxicol, 2013, 53: 161-185.
  • 3OLIVER JM. Transporters[M]//EDWARD K. Drug-like properties : concepts, structure design and methods. Salt lake: Academic Press, 2008: 103-121.
  • 4THOMAS NT. Membranes and Distribution[M]//MALCOLM R. Clinical pharmacokinetics and pharmacodynamics: concepts and applications (fourth). Philadelphia: Lippincott Williams & Wilkins, 2010: 46-67. F.
  • 5DA. Drug interaction studies--study design, data analysis, implications for dosing, and labeling recommendations[EB/OL], (2012-02-21)[2013-11-16]. http ://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm292362. pdf.
  • 6THOMAS J, WANG L, CLARK RE, et al. Active transport of imatinib into and out of cells : implications for drug resistance[J]. Blood, 2004, 104(12): 3739-3745.
  • 7WHITE DL, SAUNDERS VA, DANG P, et al. Most CML patients who have a suboptimal response to imatinib have lowOCT- 1 activity: higher doses of imatinib may overcome the negative impact of low OCT- 1 activity[J]. Blood, 2007, 110 (12) : 4064-4072.
  • 8EECHOUTE K, FRANKE RM, LOOS WJ, et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2 [J]. Clin Pharmacol Ther, 2011, 89(6): 816-820.
  • 9MAHON FX, BELLOC F, LAGARDE V, et ol. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models[J]. Blood, 2003, 101 (6): 2368-2373.
  • 10ZHOU L, SCHMIDT K, NELSON FR, et al. The effect of breast cancer resistance protein and P- glycoproteinon the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3- (4- (2- (5-methyl-2-phenyloxazol-4- y|)ethoxy)phenyl)propanoic acid (PF-407288) in mice[J]. Drug Metab Dispos, 2009, 37(5): 946-955.

共引文献39

同被引文献35

引证文献4

二级引证文献20

实用药物与临床
2018年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部